Rebamipide ophthalmic solution improves signs and symptoms of dry eye disease

The tear film break-up time (TBUT), corneal and conjunctival staining score, Schirmer 1 test, and the Ocular Surface Disease Index (OSDI) were evaluated at baseline and at the 12-week visit to compare the efficacy of the study groups. Each eye drop was administered four times daily for 12 weeks.

The results of the study are:

• There was greater improvement in 1%, and 2% rebamipide groups showed in TBUT at 12 weeks from baseline compared to the placebo group.
• There was a more significant improvement in the 2% rebamipide group in the corneal staining score at 12 weeks from baseline than the placebo.
• At 12 weeks of treatment, the 1% and 2% rebamipide groups showed improvement in the Schirmer 1 test, compared to the placebo group, which did not exhibit any such improvement.
• The Rebamipide and placebo groups demonstrated significant improvements in OSDI after 12 weeks of treatment, but there was no significant disparity among the three groups.

They concluded that 1% and 2% rebamipide clear solutions are an effective therapeutic option for improving TBUT and tear volume and stabilizing the corneal staining score in DED.

Further reading:

https://bmcophthalmol.biomedcentral.com/articles/10.1186/s12886-023-03004-1